BioIntellisense Stock

biointellisense.comHealthcare / Digital HealthFounded: 2018Funding to Date: $260.65MM

BioIntelliSense is a provider of continuous health monitoring and clinical intelligence solutions for Remote Patient Monitoring (RPM) and developer of a medical-grade Data-as-a-Service (DaaS) platform designed to seamlessly capturesminute-to-minute vital signs, physiological biometrics and symptomatic events through an effortless patient experience.

Register To Buy and Sell Shares

For more details on financing and valuation for BioIntellisense, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access BioIntellisense’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BioIntellisense.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About BioIntellisense’s Stock

Can you buy BioIntellisense’s stock?
BioIntellisense is not publicly traded on NYSE or NASDAQ in the U.S. To buy BioIntellisense’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell BioIntellisense’s stock?
Yes, you can sell stock of a private company like BioIntellisense. Forge can help you sell your BioIntellisense stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is BioIntellisense’s stock price?
BioIntellisense is a privately held company and therefore does not have a public stock price. However, you may access BioIntellisense’s private market stock price with Forge Data.
What is BioIntellisense’s stock ticker symbol?
BioIntellisense does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

BioIntelliSense and UC Davis partner to remotely monitor oncology patients
BioIntelliSense has announced a continuation of its partnership with UC Davis Health, launching an in-hospital monitoring initiative for patients in need of bone marrow transplants and hematology/oncology services. Using the BioButton wearable device, the programme continuously monitors patients' vital signs, alerting clinicians to subtle shifts that may indicate potential deterioration, enabling faster, more proactive intervention. Early studies have shown that the BioButton improves clinical management of oncology patients. The companies plan to expand the initiative from in-hospital to at-home monitoring.
Dr. Jim Mault, founder and CEO of BioIntelliSense, on VatorNews podcast
BioIntelliSense CEO, Dr. Jim Mault, spoke on VatorNews podcast about the company's wearable device, BioButton, that offers continuous physiological monitoring of vital signs. He noted the device's evolution from a consumer wearable to a medical-grade product. The BioButton is designed to help address the shortage of healthcare workers by automating vital sign measurements, thereby reducing the need for bedside checks by nurses.
Updated on: Apr 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.